Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma

Xiaoyan Feng,1,2 Li Zhang,1 Chirag Acharya,1 Gang An,1 Kenneth Wen,1 Lugui Qiu,2 Nikhil Munshi,1 Yu-Tzu Tai,1 Kenneth C Anderson1

1LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
2State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College. Tianjin. China.

Running title: targeting CD38 modulates immunosuppression by Tregs

Key words: CD38; regulatory T (Treg); conventional T (Tcon); multiple myeloma (MM); Isatuximab (Isa) (SAR650984); tumor-induced Treg (iTregs); natural occurring Tregs (nTregs); PD1; CD107a; IFNγ; bone marrow stromal cells (BMSCs)

Abstract word count: 250; Text word count: 4291; Figures: 6; Reference count: 50;

Supplemental Figures: 8

Key points:
1. CD38 levels are elevated in regulatory T cells versus conventional T cells in MM patients versus normal donors

2. CD38 mAbs may overcome immunosuppression via inhibiting Treg while restoring immune effector cell function

*To whom correspondence should be addressed: Yu-Tzu Tai, Ph.D., Department of Medical Oncology, Dana-Farber Cancer Institute, M551, 450 Brookline Avenue, Boston, MA 02215. Phone: (617) 632-3875; Fax: (617) 632-2140; E-mail: yu-tzu_tai@dfci.harvard.edu; Kenneth C Anderson, M.D., Department of Medical Oncology, Dana-Farber Cancer Institute, M557, 450 Brookline Avenue, Boston, MA 02215; E-mail: kenneth_anderson@dfci.harvard.edu
Translational Relevance

CD38 mAb Isatuximab (Isa), as a monotherapy and in combinational use, have shown significant clinical activities against human multiple myeloma (MM). Here we characterize that CD38 levels are higher in CD4+CD25<sup>high</sup>Foxp3<sup>+</sup> Treg versus Tcon (CD4+CD25<sup>-</sup>) and MM patients have increased percentages of CD38<sup>high</sup> Tregs than normal donors. Importantly, Isa inhibits suppressive function of Tregs highly expressing CD38 by decreasing their percentages, reducing immune inhibitory cytokines (TGFβ, IL10), and blocking their trafficking. Isa further enhances NK- and CD8<sup>+</sup> T effector cell-mediated anti-tumor immune responses, which can be further enhanced by IMiDs. In ex vivo cocultures, MM cells significantly induce functional Treg (iTreg) highly expressing CD38 and suppressing Tcon. Furthermore, increased circulating iTreg in MM patients are derived from Tcons in both cell-cell contact-dependent and -independent manners. Importantly, Isa blocks these processes. Targeting CD38 with Isa may therefore induce immunomodulatory effects which both relieve immunosuppression and trigger anti-MM immunity.
Abstract

Purpose: We study CD38 levels in immunosuppressive CD4+CD25highFoxp3+ Tregs and further define immune modulating effects of a therapeutic CD38 monoclonal antibody (mAb) Isatuximab (Isa)/SAR650984 in multiple myeloma (MM).

Experimental Design: We evaluated percentages of CD38-expressing subsets in Tregs from normal donors and MM patients. PBMCs were then treated with Isa with or without Lenalidomide (Len) or Pomalidomide (Pom) to identify their impact on percentage and immunosuppressive activity of Tregs on CD4+CD25- T cells (Tcons). We investigated the mechanism of increased Tregs in MM patients in ex vivo cocultures of MM cells with PBMCs or Tcons.

Results: CD38 expression is higher on Tregs than Tcons from MM patients versus normal donors. CD38 levels and the percentages of CD38^{high} Tregs are increased by Len and Pom. Isa preferentially decreases Treg and increases Tcon frequencies, which is enhanced by Pom/Len. Isa reduces Foxp3 and IL10 in Tregs and restores proliferation and function of Tcons. It augments MM cell lysis by CD8+ T and natural killer cells. Coculture of MM cells with Tcons significantly induces Tregs (iTregs), which express even higher CD38, CD25, and FoxP3 than natural Tregs. This is associated with elevated circulating CD38+ Tregs in MM patients vs.
normal donors. Conversely, Isa decreases MM cell- and bone marrow stromal cell-induced iTreg by inhibiting both cell-cell contact and TGFβ/IL10. Finally, CD38 levels correlate with differential inhibition by Isa of Tregs from MM vs normal donors.

**Conclusion:** Targeting CD38 by Isa can preferentially block immunosuppressive Tregs and thereby restore immune effector function against MM.
INTRODUCTION

Monoclonal antibodies (mAbs) targeting SLAMF7 and CD38 have become available to treat relapsed/refractory (RR) multiple myeloma (MM). Specifically, the first CD38 mAb daratumumab was approved in 2015 to treat RR MM (1) and is effective as a monotherapy (2,3). Isatuximab (Isa)/SAR650984 (4), another therapeutic CD38 mAb currently under clinical development, also shows significant clinical activity in heavily pretreated patients with RR MM, both as a monotherapy and combined with Lenalidomide (Len)/Dexamethasone (Dex) (5). In addition to Fc-dependent cytotoxicity mediated by IgG1-based CD38 mAbs, Isa induces direct killing of p53-mutated MM cells expressing high levels of CD38 in ex vivo cultures without effector cells and Fc cross-linking reagents (6). Isa significantly kills CD38\textsuperscript{high}-expressing MM cells via induction of homotypic aggregation, leakage of lysosome-associated cathepsin B and lysosomal associated membrane protein-1 (LAMP-1), and generation of reactive oxygen species (6). Furthermore, apoptosis is significantly enhanced when Isa is combined with Pomalidomide (Pom)/Len (6). Since CD38 is widely expressed on hematopoietic cells, it is important to study whether Isa also has impact on these cells. To date, the effects of Isa on CD38-expressing immune cells and modulation of immune function is not defined.

Regulatory T cells (Tregs) play a crucial role in immune surveillance by suppressing activation, expansion, and function of target cells including CD4+CD25- conventional T cells (Tcons), cytotoxic CD8+ T cells, as well as Natural Killer (NK) cells (7). They inhibit both cellular and humoral immune responses (8,9). Two forms of Tregs, “natural” and “induced” have been reported (10,11). Naturally occurring Tregs (nTregs), which constitute 5%-10% CD4+ lymphocytes, originate in the thymus and disseminate to periphery. Induced Tregs (iTregs) are generated in the periphery by soluble cytokines and cell-cell contact (10-12).
In parallel, tumor cells have the capacity to avoid immune recognition, to induce immune cell dysfunction, and to escape from immune surveillance via Tregs (9,13). The proportions of Tregs are elevated in the circulation of patients with solid tumors and hematologic malignancies (14-19). Increasing levels of Tregs often correlate with tumor burden and disease progression (16,19-22). Accumulation of Treg in the tumor microenvironment is associated with reduced survival (15,17,18,23). Moreover, anti-tumor immune responses are enhanced in animal models after Treg depletion using mAbs against surface markers highly expressed on Tregs, i.e., CD25 (24), CTLA-4 and OX40 (25-27), and in transgenic DEREG mice (28). Thus, Tregs present a promising therapeutic target to restore anti-tumor immune responses.

CD38 is expressed on several lineages of hematopoietic cells including Tregs, and its levels correlate with the suppressive function of Tregs. CD38-knockout mice present with a loss of Foxp3+ regulatory T cells (29,30). Conversely, high CD38 expression may define a highly suppressive subset of Tregs (31-33). We here characterize the role of CD38 in Treg inhibitory function both on Tcons and other immune effector cells in MM. We then show that Isa, alone or with Len/Pom, modulates the frequency and function of Tregs dependent on CD38, thereby restoring immune effector function in MM.

MATERIALS AND METHODS

Cell lines, medium and reagents

Human multiple myeloma cell lines (U266, RPMI8226) were cultured in mycoplasma free condition and maintained in complete culture medium (RPMI 1640 medium supplemented by 10% FBS, 2 mM L-Glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin) in ventilated tissue culture flasks at 37°C in a 5% CO₂ humidified incubator.
Peripheral blood nuclear cells (PBMCs) were collected from fresh buffy coat of healthy donors and MM patients after informed consent, in accordance with the Declaration of Helsinki and under the auspices of a Dana-Farber Cancer Institute Institutional Review Board approved protocol. PBMC were expanded in complete culture medium with 20 IU/ml rIL2 (Miltenyi Biotec, Germany). Isatuximab and its F(ab’)2 fragments were obtained from Sanofi (Cambridge, MA) (4,6). Len/Pom were purchased from Selectchem, anti-PD1/PD-L1 mAb from Biolegend (San Diego, CA), and Mitomycin C from Sigma-Aldrich (St Louis, MO).

**Proliferation assay for Tregs and Tcons**

PBMCs from normal donors were pretreated with or without 1μM Len/Pom for 3d, stained by 5μM CFSE (Invitrogen), and then plated in the presence or absence of indicated doses of Isa. Following 5d incubation, proliferating Tregs and Tcons were identified as CFSE-diluted subsets in CD4+CD25\(^{high}\)Foxp3+ Tregs and CD4+CD25- Tcons, respectively. Unlabeled cells were used as a control.

**Phenotyping and FACS analyses**

Antibodies used for flow cytometry were as follows: CD4-Pacific Blue, CD25-PE, CD25-APC, CD127-FITC, Foxp3-PE, CD38-PE-Cy7, AnnexinV-PE, PD1-APC, CD8-FITC, CTLA4-PE-Cy7, CD44-FITC, CD62L-FITC, ICOS-FITC, GITR-PE, OX40-FITC, CD138-FITC, PD-L1-PE, and their isotype-matched mAbs (all from Biolegend). Intracellular staining of Foxp3, CTLA4, GITR, and OX40 were performed after fixation and permeabilization using cytofix/cytoperm kit (BD Biosciences), according to manufacturer’s protocol. Tregs were gated as CD4+CD25\(^{high}\)Foxp3+ cells in CD4+ population and then sequential markers were assayed on Tregs, whereas CD4+CD25- cells were identified as Tcons. The remaining CD4+CD25\(^{low}\)/intermediate subset was excluded in the current study because of their limited
immunosuppressive activity compared with CD25high population (34). To avoid the effect of permeabilization when apoptosis assay was performed, CD4+CD25highCD127low/- cells were identified as Tregs (35). All flow cytometry was performed by BD FACS CantoII, and analyzed on FlowJo software version 10 (Treestar).

**Cell purification and immunosuppressive function assay**

Tregs were purified using CD4+CD25+ Regulatory T cell Isolation Kit (Miltenyi Biotec, Germany). The purity of isolated population was >95%. Tcons were used as target cells in immunosuppressive assays. In brief, Tcons were cultured alone or with autologous Tregs in 96-well tissue culture plates in the presence of Isa, alone or with Len/Pom, and stimulated with anti-CD3/CD28 beads (Miltenyi Biotec, Germany), according to the manufacturer’s recommendation. Proliferation was measured by [3H]-thymidine incorporation.

**Activation of immune effector cells detected by degranulation (CD107a) and intracellular interferon gamma (IFNγ) production in response to MM cells**

PBMCs from normal donors or MM patients were treated with serial doses of Isa and/or 1μM Len/Pom for 2-3 d, followed by addition of MM cells at E:T ratio of 10:1 together with CD107a antibody (36). After 1h incubation, protein transport inhibitors Brefeldin A and Monensin (BD Biosciences) were added for an additional 4 h. Cells were then harvested and stained with surface markers (CD3-Pacific Blue, CD56-FITC, CD8-APC) and fixed/permeabilized, followed by staining with anti-IFNγ mAb. All Abs used were from Biolegend.

**Ex vivo co-culture in the generation of iTregs**

MM cells were pre-treated with mitomycin C to block their proliferation, followed by 3 washes. They were next co-cultured with PBMCs or Tcons in tissue culture plates. PBMCs or
Tcons alone were used as controls. Isa was added into co-cultures for 7d, followed by FACS analysis to determine frequency and phenotype of Tregs. Supernatants were also collected for cytokine assessment.

**Statistical analyses**

Results are shown as means ± SEM or ranges, as appropriate. The student’s t test was used to compare 2 groups. One-way ANOVA test was used to compare 3 or more groups. Two-way ANOVA test was used when there were two variables. Statistical analyses were carried out with Prism software (GraphPad Software, Inc). P < 0.05 was determined to be statistically significant.

**Results**

**CD38 expression is higher on Tregs versus Tcons, and CD38^{high} subsets are increased on Tregs of MM patients versus normal donors.**

We first examined CD38 expression on CD4+CD25^{high}Foxp3+ Tregs and CD4+CD25^{-} Tcons. Three subsets were seen in Tregs and Tcons: CD38 negative (-), low, and high expression populations. In a representative sample, Tregs have higher percentages of CD38-expressing subsets with increased CD38 expression versus Tcons (63.8 % vs 17.2%; median fluorescence intensity (MFI) of 466 vs 55.7) (Figure 1A, Supplement Figure 1A). Specifically, percentages of CD38^{high} subsets are increased in Tregs vs Tcons from PBMCs of 8 normal donors (Figure 1B, left panel); conversely, frequencies of CD38^{low/-} Tregs are decreased in Tregs compared with Tcons (Supplement Figure 1B, lower panel). MFIs of CD38 are higher for Tregs vs. Tcons (Supplemental Figure 1C). Significantly, percentages of CD38^{+}subset (Supplement Figure 1D-E) and CD38^{high} Tregs are increased in MM patients (n=11) vs normal donors (n=8) (Figure 1B,
right panel; Figure 1C). Levels of CD38 correlate with Foxp3 in Tregs of MM patients (n=11, Figure 1D). Moreover, MM patient Tregs inhibit proliferation of autologous Tcons, as demonstrated by significantly decreased percentages of CFSE dilution (Figure 1E, Supplement Figure 1F).

**CD38 expression on Tregs is upregulated by IMiDs**

We next assessed the impact of Len/Pom on CD38 expression on viable Tregs. Low dose (1μM) len and pom significantly increase MFI of CD38 on Tregs after 3d and persisting until 10d; moreover, the higher percentage CD38+Tregs was maintained relative to control medium (Figure 2A). In addition to higher CD38 on Tregs from MM patients vs normal donors, Len or Pom enhances cell surface CD38 on Tregs of MM patients and normal donors (Supplemental Figure 2). Specifically, Len or Pom increases 2-3 fold the percentage of CD38\textsuperscript{high} (CD38hi) subsets and the MFI of CD38 on Tregs in PBMCs from MM patients (Figure 2B-C). These results suggest that IMiDs may enhance sensitivity of viable Tregs to Isa.

**Isa decreases Treg frequencies and inhibits Treg-suppression of Tcon proliferation, which is enhanced by IMiDs**

When PBMCs from normal donors (n=10) were treated with or without Isa (1μg/ml) for 3 days, the frequency of Tregs in CD4+ cells is reduced from 8.88±0.66% at baseline to 4.56±0.77% (p<0.01) (Figure 3A, Supplemental Figure 3A). In contrast, Tcons are increased from 63.70±7.51% to 75.83±5.87% (p<0.05), associated with decreased ratios of Tregs/Tcons. In MM patient samples (n=6), even 0.1 μg/ml of Isa decreases Tregs (16.35±1.62% at baseline to 7.34±1.78%, p<0.01) and stimulates Tcons (from 69.03±4.89% to 81.69±2.55%, p<0.05), associated with reduced Tregs/Tcons ratios (Figure 3B, Supplemental Figure 3B). Thus, higher CD38 expression on Tregs from MM patients versus normal donors correlates with increased Isa inhibition of MM
Tregs. Notably, F(ab)’2 fragments of Isa are sufficient to decrease Tregs and stimulate Tcons (Figure 3C, Supplemental Figure 3C), confirming that the blockade of Tregs is CD38-specific and Fc-independent.

Pom alone, more potently than Len, reduces Tregs and stimulates Tcons (Figure 3A-B, Supplemental Figure 3A-B). Consistent with upregulation of CD38 on Tregs, pre-treatment of PBMCs with Len/Pom for 3-5d enhances Isa-induced inhibition of Tregs from both normal donors and MM patients, evidenced by further decreased Tregs/Tcons ratios (Figure 3A-B).

We next determined whether Isa modulates the suppressive activity of Tregs on Tcons. Co-cultures of Tregs with autologous Tcons diminished proliferation of Tcons from 100% to 27.35±2.99%; conversely, Isa suppresses the inhibition of Tregs on Tcon proliferation in a dose-dependent manner (Figure 3D, Supplemental Figure 3D).

**Isa induces apoptosis and inhibits proliferation and migration of Tregs**

We next evaluated mechanisms of Isa-induced cytotoxicities against Tregs. Isa (0.1 μg/ml) induces approximately 2-fold higher percentage annexin V+ Tregs than control media (Figure 4A-B, A, normal donors; B, MM patients) or isotype IgG1 (data not shown), which is further enhanced by Len or Pom (Figure 4A). The impact of Isa on proliferation of Tregs was examined by staining PBMCs with CFSE for 5d, followed by flow cytometry analysis gated on Tregs. Isa decreases proliferation of Tregs in a dose-dependent manner, which is enhanced by Pom more potently than Len (Figure 4C). In contrast, Len or Pom alone slightly induce apoptosis and significantly decrease proliferation of Tregs in ex vivo culture.

Using real time qRT-PCR, Isa decreased Foxp3, a key immunosuppressive transcriptional factor, in Tregs from normal donors and MM patients (Figure 4D, Supplemental Figure 4). Inhibitory cytokine IL10 is also reduced in Isa-treated Tregs (Figure 4D).
Isa enhances CD8+ T and NK-mediated lysis of MM cells, which is further enhanced by Len/Pom

Since Tregs also influence NK and CD8+ T effector cells, we next assessed the effects of Isa on their function. PBMCs from 3 normal donors were treated for 3d with Isa, with or without Len/Pom (1 μM), prior the addition of RPMI8226 MM cells and flow cytometry analysis. Upregulation of cell surface CD107a and interferon (IFN) γ production is associated with cytotoxicity induced in these effector cells (36). Isa increases percentages of CD107a and IFNγ in immune effector cells of normal donors (Supplemental Figure 5A-B), whereas an isotype control IgG1 mAb has no effects (data not shown). Isa (0.1 μg/ml) significantly increases the ability of these two immune effector cells to lyse target MM cells, confirmed by depletion of CD138+ MM cells in these cultures (data not shown). Although low dose Len or Pom (1 μM) alone for 3d minimally increased both CD107a and IFNγ, combined treatment of Isa with Pom, more potently than Len, further augments activation of these effector cells (Supplemental Figure 5A-B). Importantly, Isa, in a dose-dependent manner, upregulates effector function of CD8+ T and NK cells from MM patients (n=3) (Figure 5A-B), which is further augmented by Pom, more potently than Len.

Tumor cells induce generation of iTregs

We found that circulating Tregs in MM patients are significantly higher compared with normal donors (Figure 6A), as in previous reports (20,22,37). This could be due to generation of Tregs in the periphery, designated as tumor-induced Tregs (iTregs) derived from naïve CD4+ cells or CD4+CD62L+ central memory cells (38-41). To study whether such a mechanism leads to elevated percentage Tregs in MM patients, PBMCs were co-cultured with MM cells for 7d, followed by flow cytometry analysis. Using the same CD4+CD25highFoxp3+ gating strategy,
the frequency of Tregs in CD4+ populations significantly increases when co-cultured with either RPMI8226 or U266 MM cells (Supplemental Figure 6A, left panels). To further identify the origin of these iTregs, purified Tcons were co-cultured with MM cells. MM cells induce even more iTregs from Tcons than from whole PBMC populations (Supplemental Figure 6A, right panels): fold increases in iTreg induced by MM cells were significantly higher from Tcons (n=11) than PBMCs (n=5) (Supplemental Figure 6B). We found that iTregs in cocultures of PBMCs with MM cells increase expression of CD38 with time (Supplemental Figure 6C). Fold induction in CD38 levels is significantly higher in iTregs vs nTregs in ex vivo co-cultures containing low dose IL-2 (Figure 6B). Importantly, proliferation of autologous Tcons is inhibited by iTregs induced by MM cells in these ex vivo cocultures (Figure 6C). Whether the source of iTreg is PBMCs or Tcons, their phenotype is characterized by higher CD38, CD25, Foxp3, CD44, ICOS, and PD1, as well as lower CD127 expression, compared with nTregs (Supplemental Figure 6C-E). Changes in these cell surface proteins are even more significant on iTregs derived from Tcons vs PBMCs, following culture with multiple CD38\text{low/-}M cell lines (Supplemental Figure 6C-E).

We next studied mechanisms of iTregs generation. PD-L1 is concurrently increased on MM cells in these cocultures (Supplemental Figure 7A). Conditioned media from MM cells increase frequency of iTregs (Supplemental Figure 7B), indicating the importance of cytokines secreted from MM cells in the induction of iTregs. Specifically, both TGF\beta and IL10 are significantly increased in supernatants from co-cultures of MM cells with either PBMCs or Tcons (Supplemental Figure 7C, Figure 6E). Stronger induction of both cytokines from Tcons vs PBMCs correlates with greater extent of iTregs generation from Tcons vs. PBMCs (Supplemental Figure 6B & 7C). Neutralizing anti-TGF\beta, -PD1, and -PD-L1 mAb partially
blocked iTregs induction (Supplemental Figure 7D-E), supporting their roles in generation of iTregs. Combined with decreased induction of iTregs when using transwell plates to separate Tcons from MM cells, these data indicate that cell-to-cell contact also contributes to the generation of iTregs (data not shown).

**Isa also significantly inhibits tumor- and bone marrow stromal cell-induced Tregs (iTregs) which highly express CD38**

We next determined whether Isa inhibits MM cell-induced iTregs which express high levels of CD38 (Figure 6B, Supplemental Figure 6C-E). Isa blocks induction of iTregs from PBMCs (Figure 6D) and from Tcons (Supplemental Figure 8A) in ex vivo co-cultures with U266 MM cells. Similar levels of apoptosis were observed in both Isa-treated and untreated CD38-negative U266 MM cells, evidenced by annexin V/PI-based flow cytometry analysis (Supplementary Figure 8B), excluding the possibility that failure of U266 cells to induce iTregs was due to tumor cell killing by Isa. TGFβ and IL10 were significantly elevated in supernatants from cocultures of PBMCs with U266 MM cells and significantly reduced by Isa (Figure 6E). Since these cytokines are critical in iTregs generation, we also examined whether BM stromal cells (BMSCs) induce generation of iTregs. Cocultures of PBMCs with adherent BMSCs from MM patients increased the percentage of Tregs, which was also inhibited by Isa (Supplementary Figure 8C). These results indicate that CD38 mAb is capable of blocking iTregs in the BM microenvironment. Finally, Isa decreases the percentage of Tregs from MM patients more efficiently than those from normal donors: MM patients baseline 15.98±1.19% reduced to 5.87±0.54% at 0.1μg/ml Isa, n=13; normal donors baseline 7.54±0.68% decreased to 4.96±0.57% at 0.1μg/ml Isa, n=15 (Figure 6F).
DISCUSSION

Tregs, as regulatory elements, actively suppress immune responses and represent a predominant tolerance-inducing modality. Conversely, blockade of Tregs may reverse the suppressive immune environment via promoting T cell activation and cytotoxicity, thereby allowing the immune system to efficiently attack the tumor. We here demonstrate that targeting CD38 by Isa, as recently reported by daratumumab,(32) preferentially blocks Tregs greater than Tcons due to increased CD38 levels on Tregs. Since CD38^{high} Tregs exhibit even higher immunosuppressive ability (32,42), targeting CD38 can abrogate this subset more effectively than CD38^{low} or negative subsets, thereby relieving the immunosuppressive BM microenvironment. We show that blockade of Tregs by Isa restores Tcons and upregulates cytolysis of MM cells mediated by cytotoxic T and NK cells, which is further enhanced by IMiDs.

Our studies show that Isa reduces the frequency of Tregs and blocks their suppressive function on Tcons from both normal donors and MM patients. The increased proportion of Tcons after Isa treatment is due to significantly increased proliferation of Tcons. Correspondingly, the ratio of Tregs to Tcons (Tregs/Tcons) significantly decreased following Isa treatment. Fc-independent mechanisms including apoptosis and decreased proliferation could account for Tregs inhibition, in addition to antibody-dependent cytotoxicity (ADCC) and antibody-dependent phagocytosis mediated by Fc-expressing NK and macrophages. Our studies show that Isa preferentially induces apoptosis of Tregs greater than Tcons due to increased percentages of CD38+ Tregs with higher CD38 expression than Tcons. CD38^{high} Tregs, which have even greater immunosuppressive capacity than CD38-/low Tregs (32), are most sensitive to
CD38 targeting. In addition, Isa decreases Foxp3 and IL10 in viable Tregs, further targeting the immunosuppressive function of Tregs. It remains to be determined whether such differential effects of Isa on Tregs vs Tcons can increase its therapeutic window.

Besides blocking the suppressor cell component, Isa spares Tcons, CD8+ T cells, and NK cells, consistent with the limited toxicity observed in clinical trials (5,43). Isa significantly increases CD8+ T- and NK cell-mediated anti-MM immune response, with enhanced induction of CD107a and IFNγ. Inhibition of immune effector cells by suppressor Tregs is blocked following treatment of PBMCs with Isa for at least 2d. Considering the underlying immune deficiency of MM patients, targeting Tregs to restore effective anti-tumor response represents a promising treatment strategy. Importantly, Isa targets CD38high Tregs in an Fc-independent manner, even in MM patients with a highly impaired immune system.

IMiDs inhibit proliferation and function of Tregs in vitro (44,45). However, reports of Treg frequency in patients treated with len are variable. In CLL patients, len treatment reduced proportion of Tregs (46). Conversely, a delayed increase of Tregs after treatment with len has been reported in MM in the setting of induction, maintenance, or salvage treatment with Len or Pom (22,35,47,48). Elevated Tregs in vivo after immune stimulation by Len may represent a negative feedback loop to maintain immune homeostasis. Indeed, our data shows that IMiDs reduce Tregs and stimulate Tcons in vitro. Importantly, low dose Len/Pom with Isa enhances suppression of Tregs and induces immune effector cell-mediated MM cell lysis in vitro. Mechanistically, Len and Pom up-regulate CD38 levels on viable Tregs and increase the percentage of CD38high Tregs, thereby conferring further sensitivity to Isa treatment.

Increasing evidence indicates that patients with cancer may have higher proportions of Tregs, which may serve as a predictor for survival. Importantly, increased circulating functional Tregs
have been noted in MM patients compared with normal donors (22,37). Increased Tregs in patients with cancer can be derived from naïve CD4+ T cells by stimulation with tumor cells and tumor bystander cells. Using an ex vivo coculture system to mimic the in vivo BM microenvironment, we showed that MM cells are able to induce generation of iTregs from both PBMC and Tcons. Specifically, iTregs are induced when co-culturing MM cells with purified Tcons in the absence of antigen-presenting cells. Furthermore, when compared with nTregs, iTregs express even higher cell surface CD38, Foxp3, CD25, CD44, ICOS and PD1, as well as lower levels of CD127. This suggests an even greater suppressive function of iTregs, further supporting targeting CD38 to block these highly immunosuppressive Tregs derived from Tcons. In addition, PD-L1 is increased on MM cells in these cocultures, which may further promote differentiation of Tcons into Tregs via ligation with PD1 (49). PD-L1 upregulation on MM cells mediates adherence to BM stromal cells and induction of MM-related cytokines, which further increases immunosuppression in the BM microenvironment (42). These results suggest the utility of combining Isa with PD-L1 mAb to enhance anti-MM immunity.

Both soluble cytokines and cell-to-cell contact are critical in the generation of iTregs. On one hand, inhibitory cytokines IL10 and TGFβ in the culture supernatant are significantly increased when tumor cells are present. Indeed, a blocking anti-TGFβ mAb partially inhibits generation of iTregs. Conditioned media from MM cells also induces Tregs from PBMCs, supporting a soluble cytokine mechanism. On the other hand, separating Tcons and MM cells by transwell plates attenuates induction of iTregs. Moreover, membrane PD-L1 expression is upregulated on MM cells in parallel with increased PD1 receptor on Tregs. Either anti-PD1 mAb or anti-PD-L1 mAb can inhibit induction of iTregs, indicating a role of surface receptor-ligand interaction in this process. Our current findings are consistent with the notion that induction of
CD25+Tregs from CD25-Tcons was partially abrogated when Tcons were separated from tumor cells (40), indicating a role for cell-cell contact.

Our data show that Isa prevents induction of iTregs by MM cells and bone marrow microenvironment cells, associated with reduced TGFβ and IL10 in the coculture supernatants. Potential mechanisms whereby Isa attenuates iTregs generation include: (1) iTregs express higher levels of CD38 than nTregs, making them even more sensitive to Isa; and (2) soluble cytokines contribute to generation of iTregs, and Isa may reduce IL10 production through blocking CXCL12/CXCR4 signaling. For example, CXCL12 costimulates IL10 secretion by a diverse population of CD45RA- T cells, including Tregs (50). Blocking CD38 impairs CXCL12/CXCR4 signaling pathway in CLL cells (51). Whether this occurs in Tregs remains to be determined.

In summary, Isa suppresses the inhibitory function of Tregs which highly express CD38 by decreasing their cell number, inhibiting immunosuppressive cytokines, and blocking their trafficking. Isa enhances NK- and CD8+ T effector cell-mediated anti-tumor immune responses, which can be further enhanced by IMiDs. Furthermore, increased circulating iTregs in MM patients are derived from Tcons in both cell-cell contact-dependent and -independent manners. Importantly, Isa blocks these processes. Targeting CD38 with Isa may therefore induce immunomodulatory effects which both relieve immunosuppression and trigger anti-MM immunity.

ACKNOWLEDGEMENTS

The authors thank Dr. Francisco Adrian, Zhili Song at Sanofi for providing reagents and Dr. Hua Jiang, and Alireza Kalbasi for helpful input and excellent technical assistance. The authors thank
all clinical and laboratory members of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute for support and help for this study.

**Funding**

National Institutes of Health Grants RO1CA050947, RO1CA207237, RO1100707, and DF/HCC SPORE in Multiple Myeloma P50CA100707; K.C.A. is an American Cancer Society Clinical Research Professor.

**AUTHOR CONTRIBUTIONS**

X.F., Y.-T.T., K.C.A. conceptualized research and formed the hypothesis of this paper; X.F., C.A., G.A., K.W., L.Z. designed, performed experiments, collected, and analyzed data; C.A., G.A., L.Q. provided reagents and analytic tools; N.M., K.C.A. provided MM patient samples; X.F., Y.-T.T. wrote the manuscript; Y.-T.T., K.C.A. critically evaluated and edited the manuscript.

**CONFLICT OF INTEREST**

N.M. serves on advisory boards to Millennium, Celgene, Novartis, and a scientific founder of Oncopep. K.C.A. serves on advisory boards to Onyx, Celgene, Gilead, and is a scientific founder of Acetylon, Oncopep, and C4 Therapeutics. The remaining authors declare no competing financial interests.
REFERENCES


11. Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front...


of Tumor-Derived TGF- The Journal of Immunology 2007;178(5):2883-92 doi 10.4049/jimmunol.178.5.2883.


Figure Legends

Figure 1  CD38 level is higher on Treg versus Tcon and percentages of CD38high subset in Tregs are significantly increased in MM patients versus normal donors.

(A) The percentage and median fluorescence intensity (MFI) of CD38high, low, and negative (-) subsets were determined within CD4+CD25high(hi)Foxp3+Tregs (black arrow) and CD4+CD25- Tcons (open arrow). (B) Shown are summary (means ± SDs) of percentages of CD38high on Tregs versus Tcons from PBMCs of 8 normal donors (left panel). Right panel shows percentages of CD38high on Tregs from 11 MM patients and 8 normal donors. (C) Shown are plots of CD38 on Tregs from a representative MM patient and normal donor. (D) Levels of CD38 correlate with Foxp3 in Tregs of 11 MM patients. (E) Treg inhibits proliferation, assessed by CFSE dilution in Tcons, of autologous Tcons from MM patients. Stimilation is done using anti-CD3/CD28 beads. **P< 0.01, ****P< 0.001

Figure 2  CD38 expression is upregulated by IMiDs, associated with elevated CD38high Tregs.

(A) PBMCs (n=3) were incubated with Len or Pom followed by flow cytometry analysis for CD38 levels (MFI) on Tregs and percentage of CD38-expressing Tregs. Shown are Means ± SEMs. (B) Shown are representative plots of CD38-expressing subsets in gated CD4+CD25hiFoxp3+ Tregs from a MM patient treated with indicated drugs for 7 days. MFI (underlined) and frequency of CD38-/low/high(hi) subsets are also indicated. (C) Frequencies of CD38-/low/hi Tregs of MM PBMCs were followed.
Figure 3  Isa reduces Treg frequencies and blocks Treg-inhibited proliferation of Tcons, which is enhanced by IMiDs.

PBMCs from normal donors (A, n=10) or MM patients (B, n=7) were pretreated with 1µM Len or Pom for 3-5 days followed by incubation with Isa, alone or with Len/Pom, for another 3 days. Flow cytometry was used to determine the percentage of Tregs and Tcons in CD4+ lymphocytes. Tregs/Tcons is then normalized to untreated controls (lower panel) and fold changes (Means ± SEMs) are shown. Untreated cells are used as controls in all the setting. (C) PBMCs from 4 MM patients were treated with either Isa (whole IgG1) or its F(ab)’2 fragments and the percentage of Tregs is determined by flow cytometry. (D) Purified Tcons were incubated with or without autologous Tregs isolated from PBMCs at 1:1 ratio for 5 days in the presence of anti-CD3/CD28 activation beads, with indicated concentrations of Isa. Proliferation was assessed by [3H] thymidine incorporation added for the last 8h. Results are shown as fold changes relative to day 0. *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001.

Figure 4  Isa induces cytotoxicity and inhibits immunosuppressive molecules of Tregs.

Isa-induced cytotoxicity in Tregs from normal donors (A) and MM patients (B) is shown as percentage of annexin V+ cells in Tregs. Shown are Means ± SEMs of 3 independent experiments. (C) PBMCs were stained with 5µM CFSE and incubated with indicated drugs for 5 days followed by flow cytometry analysis to determine percentage of diluted CFSE in Tregs. (D) Tregs were purified from PBMCs of normal donors treated with or without 1µg/ml Isa for 1d followed by real-time qRT-PCR assay for Foxp3 and IL10. Shown are fold changes relative to control groups after normalization with GAPDH control. *P< 0.05
Figure 5  Isa augments CD8+ T and NK-effector cell-mediated cytotoxicity against MM cells, which is further enhanced by Len/Pom

PBMCs from MM patients were pretreated with Isa, alone or with Len/Pom for 2-3 days, and then RPMI8226 MM cells were added at E:T ratio of 10:1 for 5h, followed by flow cytometry analysis for cell membrane CD107a and intracellular IFNγ. Dot plots are shown for CD107a (left panel) and IFNγ (right panel) in CD3+CD8+ T cells (A) and NK cells (B) of MM patient PBMCs treated as indicated.

Figure 6  MM cells induced-Tregs (iTregs) highly express CD38 and are blocked by Isa

(A) Percentages of Tregs in CD4+ lymphocytes were determined in normal donors (n=27) and MM patients (n=26). Shown are median ± ranges. (B) CD38 levels were examined at indicated time periods in iTregs (triangle) vs. nTreg (square) in PBMC cocultured with or without CD38low/- U266 cells in low dose IL-2-containing culture media. (C) CFSE-labeled Tcons cocultured with either nTregs isolated from normal donors or iTregs isolated from MM cell induction in ex vivo coculture system were stimulated with (stimulation) or without (no) anti-CD3/CD28 beads for 6 d. Proliferation were determined by percentage of CFSE dilution in Tcons. (D) Percentages of iTregs were determined in co-cultures of MM cells with PBMCs (n=4) treated with indicated doses of Isa for 7 days. Shown are Means ± SEMs. (E) Supernatants of ex vivo co-cultures (in D) were assayed for TGFβ (upper panel) and IL10 (lower panel) by ELISA. (F) PBMCs from healthy donors (n=15) and MM patients (n=13) were treated with Isa, and percentage Tregs in CD4+ lymphocytes was measured by flow cytometry analysis. Shown are Means ± SEMs. *P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001
Figure 1

A. Flow cytometry analysis of CD4+CD25hi Foxp3+ cells.

B. Comparison of CD38high subset (%) in Treg vs Tcon.

C. Flow cytometry analysis of Tregs in MM vs normal.

D. Correlation between MFI of Foxp3 and CD38 in Tcon.

E. CFSE dilution in Tcons and Tregs+Tcons.

Treg: CD4+CD25hiFoxp3+

Tcon: CD4+CD25hiFoxp3+

CD38high subset (%) in Treg vs Tcon

% CFSE dilution in Tcon

MM vs normal

Tcons vs Tregs+Tcons

no vs stimulated
**Figure 2**

**A**

MFI of CD38 on Tregs

- CNT
- LEN
- POM

% of CD38+/Tregs

- CNT
- LEN
- POM

Day 1, Day 3, Day 7, Day 10

**B**

MFI

- CNT
- Len 1μM
- Pom 1μM

% of CD38

- CNT
- Len 1μM
- Pom 1μM

CD25

- CNT
- Len 1μM
- Pom 1μM

**C**

- CNT
- Len 1μM
- Pom 1μM

% of CD38 low/Tregs

- CNT
- Len 1μM
- Pom 1μM

% of CD38 high/Tregs

- CNT
- Len 1μM
- Pom 1μM

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Research.

Figure 4

A

% annexin V/ Tregs

CNT Isa 0.1

+Len

+Pom

Isa (µg/ml) 0 0.1 1

B

% annexin V/ Tregs

CNT Isa 1 µg/ml

Isa (µg/ml) 0 0.1 1

1.2

1

0.8

0.6

0.4

0.2

0

CNT

Isa 1 µg/ml

C

CNT

Isa 0.1 µg/ml

Isa 1 µg/ml

D

Folg change

(normalized expression)

CNT

Isa 1 µg/ml

Foxp3

IL10

Events

Len

1 µM

Pom

1 µM
Figure 5

A

CD8+ T

<table>
<thead>
<tr>
<th>Condition</th>
<th>CD107a</th>
<th>IFNγ</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNT</td>
<td>1.68</td>
<td>1.28</td>
</tr>
<tr>
<td>Isa 0.1µg/ml</td>
<td>2.68</td>
<td>2.31</td>
</tr>
<tr>
<td>Isa 1µg/ml</td>
<td>3.82</td>
<td>4.52</td>
</tr>
<tr>
<td>Len</td>
<td>2.00</td>
<td>0.87</td>
</tr>
<tr>
<td>Len+Isa 0.1µg/ml</td>
<td>3.16</td>
<td>2.15</td>
</tr>
<tr>
<td>Len+Isa 1µg/ml</td>
<td>4.63</td>
<td>3.67</td>
</tr>
<tr>
<td>Pom</td>
<td>2.15</td>
<td>1.11</td>
</tr>
<tr>
<td>Pom+Isa 0.1µg/ml</td>
<td>3.52</td>
<td>1.85</td>
</tr>
<tr>
<td>Pom+Isa 1µg/ml</td>
<td>4.74</td>
<td>3.69</td>
</tr>
</tbody>
</table>

SSC

B

NK cells

<table>
<thead>
<tr>
<th>Condition</th>
<th>CD107a</th>
<th>IFNγ</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNT</td>
<td>5.41</td>
<td>4.25</td>
</tr>
<tr>
<td>Isa 0.1µg/ml</td>
<td>14.6</td>
<td>10.8</td>
</tr>
<tr>
<td>Isa 1µg/ml</td>
<td>18.8</td>
<td>19.0</td>
</tr>
<tr>
<td>Len</td>
<td>3.80</td>
<td>1.30</td>
</tr>
<tr>
<td>Len+Isa 0.1µg/ml</td>
<td>14.0</td>
<td>7.27</td>
</tr>
<tr>
<td>Len+Isa 1µg/ml</td>
<td>19.8</td>
<td>16.1</td>
</tr>
<tr>
<td>Pom</td>
<td>4.72</td>
<td>2.72</td>
</tr>
<tr>
<td>Pom+Isa 0.1µg/ml</td>
<td>14.2</td>
<td>12.7</td>
</tr>
<tr>
<td>Pom+Isa 1µg/ml</td>
<td>24.9</td>
<td>25.3</td>
</tr>
</tbody>
</table>
Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma

Xiaoyan Feng, Li Zhang, Chirag Acharya, et al.

Clin Cancer Res  Published OnlineFirst March 1, 2017.

Updated version
Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-16-3192

Supplementary Material
Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2017/02/28/1078-0432.CCR-16-3192.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.